Journal
JOURNAL OF PARKINSONS DISEASE
Volume 5, Issue 4, Pages 743-747Publisher
IOS PRESS
DOI: 10.3233/JPD-150664
Keywords
Parkinson disease; dementia; mild cognitive impairment; anticholinergics; amyloid
Categories
Funding
- Parkinson's UK grant [J-0802]
- National Institute for Health Research Newcastle Biomedical Research Unit
- Biomedical Research Centre based at Newcastle Hospitals NHS Foundation Trust
- Newcastle University
- National Institute of Health Research Biomedical Research Award
- Raymond and Beverly Sackler Studentship
- Parkinson"
- s UK [J-0802, G-1507] Funding Source: researchfish
Ask authors/readers for more resources
We evaluated the effect of anticholinergic burden on 219 participants with incident Parkinson's disease (PD) and 99 controls at study baseline and 18 months. Anticholinergic burden for each individual was calculated and summed according to the Anticholinergic Drug Scale (ADS). Medication with anticholinergic activity was more commonly prescribed in PD compared to controls, although mean ADS scores were not significantly different. Cognitive scores did not differ in PD participants taking medications with anticholinergic activity compared to those who were not. Low overall ADS scores due to increased awareness of adverse effects of medications and brevity of follow-up are potential explanations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
